These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 30779339)
1. Pharmacokinetics, Safety, and Tolerability of Tezepelumab (AMG 157) in Healthy and Atopic Dermatitis Adult Subjects. Parnes JR; Sullivan JT; Chen L; Dias C Clin Pharmacol Ther; 2019 Aug; 106(2):441-449. PubMed ID: 30779339 [TBL] [Abstract][Full Text] [Related]
2. A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Subcutaneous Tezepelumab in Healthy Japanese Men. Sakamoto K; Matsuki S; Irie S; Uchida N; Hayashi N; Horiuchi M; Ren S Clin Pharmacol Drug Dev; 2020 Oct; 9(7):833-840. PubMed ID: 31960624 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis. Zhang L; Zhang W; Xu Y; Dong L; Sun Y; Jia Y; Li Z; Chen B; Hou J; Zhang J Adv Ther; 2024 Jul; 41(7):2953-2965. PubMed ID: 38833140 [TBL] [Abstract][Full Text] [Related]
4. Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial. Simpson EL; Parnes JR; She D; Crouch S; Rees W; Mo M; van der Merwe R J Am Acad Dermatol; 2019 Apr; 80(4):1013-1021. PubMed ID: 30550828 [TBL] [Abstract][Full Text] [Related]
5. Dupilumab pharmacokinetics in Chinese healthy subjects and patients with atopic dermatitis: Results of two randomized, double-blind, placebo-controlled studies. Clot PF; Kamal M; Sun J; Xu C; Kong F; Gu Y; Yang N; Yin W; Chen B; Ming JE; Yuan Y Int Immunopharmacol; 2021 Oct; 99():107985. PubMed ID: 34435584 [TBL] [Abstract][Full Text] [Related]
6. Tezepelumab Pharmacokinetics, Safety, and Tolerability After Administration via Vial-and-syringe, Accessorized Prefilled Syringe, or Autoinjector: A Randomized Trial in Healthy Volunteers. Zheng Y; Abuqayyas L; Megally A; Fuhr R; Sałapa K; Downie J; Colice G Clin Ther; 2021 Jan; 43(1):142-155.e5. PubMed ID: 33380362 [TBL] [Abstract][Full Text] [Related]
7. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-06817024 in Healthy Participants, Participants with Chronic Rhinosinusitis with Nasal Polyps, and Participants with Atopic Dermatitis: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study. Danto SI; Tsamandouras N; Reddy P; Gilbert S; Mancuso J; Page K; Peeva E; Vincent MS; Beebe JS J Clin Pharmacol; 2024 May; 64(5):529-543. PubMed ID: 37772436 [TBL] [Abstract][Full Text] [Related]
8. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. Nemoto O; Furue M; Nakagawa H; Shiramoto M; Hanada R; Matsuki S; Imayama S; Kato M; Hasebe I; Taira K; Yamamoto M; Mihara R; Kabashima K; Ruzicka T; Hanifin J; Kumagai Y Br J Dermatol; 2016 Feb; 174(2):296-304. PubMed ID: 26409172 [TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of a humanized rabbit monoclonal antibody (SSS07) in healthy adults: Randomized double-blind placebo-controlled single ascending dose trial. Liu C; Dong W; Xia L; Lv J; Jiang D; Wang Q; Wang M; Wu M; Miao J; Tao T; Wang D; Zheng L; Su S; Liu L; Fang Y Int Immunopharmacol; 2021 Feb; 91():107263. PubMed ID: 33383447 [TBL] [Abstract][Full Text] [Related]
10. Tezepelumab in Adults with Uncontrolled Asthma. Corren J; Parnes JR; Wang L; Mo M; Roseti SL; Griffiths JM; van der Merwe R N Engl J Med; 2017 Sep; 377(10):936-946. PubMed ID: 28877011 [TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-controlled phase I study. Yang L; Fang Y; Luo Y; Fu M; Shen K; Luo Z Expert Opin Investig Drugs; 2024 Jul; 33(7):741-752. PubMed ID: 38805242 [TBL] [Abstract][Full Text] [Related]
12. DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Menzies-Gow A; Ponnarambil S; Downie J; Bowen K; Hellqvist Å; Colice G Respir Res; 2020 Oct; 21(1):279. PubMed ID: 33087119 [TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetic Modeling and Exposure-Efficacy and Body Weight-Response Analyses for Tezepelumab in Patients With Severe, Uncontrolled Asthma. Zheng Y; Abuqayyas L; Quartino A; Guan Y; Gao Y; Liu L; Hellqvist Å; Colice G; MacDonald A J Clin Pharmacol; 2024 Aug; 64(8):908-921. PubMed ID: 38632826 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects. Li Z; Radin A; Li M; Hamilton JD; Kajiwara M; Davis JD; Takahashi Y; Hasegawa S; Ming JE; DiCioccio AT; Li Y; Kovalenko P; Lu Q; Ortemann-Renon C; Ardeleanu M; Swanson BN Clin Pharmacol Drug Dev; 2020 Aug; 9(6):742-755. PubMed ID: 32348036 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma. Ly N; Zheng Y; Griffiths JM; van der Merwe R; Agoram B; Parnes JR; Roskos L J Clin Pharmacol; 2021 Jul; 61(7):901-912. PubMed ID: 33368307 [TBL] [Abstract][Full Text] [Related]
16. SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma. Wechsler ME; Colice G; Griffiths JM; Almqvist G; Skärby T; Piechowiak T; Kaur P; Bowen K; Hellqvist Å; Mo M; Garcia Gil E Respir Res; 2020 Oct; 21(1):264. PubMed ID: 33050928 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects. Khalilieh S; Hodsman P; Xu C; Tzontcheva A; Glasgow S; Montgomery D Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):294-300. PubMed ID: 29510001 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial. Worm M; Simpson EL; Thaçi D; Bissonnette R; Lacour JP; Beissert S; Kawashima M; Ferrándiz C; Smith CH; Beck LA; Chan KC; Chen Z; Akinlade B; Hultsch T; Staudinger H; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Ardeleanu M JAMA Dermatol; 2020 Feb; 156(2):131-143. PubMed ID: 31876900 [TBL] [Abstract][Full Text] [Related]